Sanofi passes on Alnylam’s breakthrough therapyAlnylam is to forge ahead with a rare disease therapy on its own after Sanofi decided to opt Share XSanofi passes on Alnylam’s breakthrough therapyhttps://pharmaphorum.com/news/sanofi-passes-alnylams-breakthrough-therapy/
Innovative Regulatory Pathways SummitDisease education to resonate with patient & provider Share XInnovative Regulatory Pathways Summithttps://pharmaphorum.com/events/innovative-regulatory-pathways-summit-2/